ImmunityBio, Inc. (IBRX) Institutional Ownership

Ownership Summary

ImmunityBio, Inc. (NASDAQ:IBRX) has 379 institutional investors with active 13F positions as of March 2026.

• These investors collectively held 17.3% of ImmunityBio's outstanding shares in March 2026, down from 19.0% in December 2025.
• Their total shares held in IBRX increased 35.3% quarter over quarter, and separately, investors owning ImmunityBio increased 80.48% from a year ago.
• Activity in IBRX broke down as 280 buyers, 61 sellers, and 38 unchanged among 379 total holders.
• Combined, these investors held 178.1Mn shares in IBRX for March 2026, up by 46.46Mn shares quarter on quarter, and up 92.54Mn shares year over year.
• BlackRock, Inc. is the top holder of ImmunityBio as of March 31, 2026, with 26.35Mn shares representing 2.57% of outstanding stock.
• The most significant purchases of IBRX for the quarter ending March 2026 came from VANGUARD PORTFOLIO MANAGEMENT LLC (16.32Mn), VANGUARD CAPITAL MANAGEMENT LLC (15.13Mn), D. E. Shaw & Co., Inc. (12.57Mn), HRT FINANCIAL LP (3.93Mn), VOLORIDGE INVESTMENT MANAGEMENT, LLC (2.93Mn).
• The largest sales of IBRX for the quarter ending March 2026 came from JANE STREET GROUP, LLC (13.52Mn), Goldman Sachs Group Inc (9.07Mn), AlphaCore Capital LLC (2.99Mn), SUSQUEHANNA INTERNATIONAL GROUP, LLP (2.48Mn), Morgan Stanley (1.09Mn).
• ImmunityBio's 10 largest shareholders as of March 2026 include BlackRock, Inc. (26.35Mn), State Street Corp (17.71Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (16.32Mn), VANGUARD CAPITAL MANAGEMENT LLC (15.13Mn), D. E. Shaw & Co., Inc. (12.57Mn), GEODE CAPITAL MANAGEMENT, LLC (8.03Mn), TWO SIGMA INVESTMENTS, LP (4.39Mn), Morgan Stanley (4.02Mn), HRT FINANCIAL LP (3.93Mn), Woodline Partners LP (3.45Mn) per Business Quant data.